U.S. drugmaker Bristol-Myers Squibb said on Tuesday it had stopped “certain initiatives” in China, when asked by Reuters to comment on industry chatter it was curbing financial incentives for prescribing doctors.
Payments to healthcare professionals in China are under intense scrutiny after GlaxoSmithKline was slapped with a record $490 million fine for bribery in 2014.
Industry sources cited reports on Chinese social media that Bristol-Myers had announced a clampdown on the use of expenses and speaker fees for doctors.
Reuters could not immediately verify the reports but a company spokesman said in an emailed statement: “Bristol-Myers Squibb has voluntarily stopped certain initiatives in China as the company continues to review its activities and build upon its business model in China.”
Last October, Bristol-Myers agreed to pay $14 million to settle U.S. Securities and Exchange claims its joint venture in China made cash payments and provided other benefits to healthcare providers in China in exchange for prescription sales.
By Ben Hirschler; Editing by Martinne Geller
Source: Reuters
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
